Dolutegravir

Overview

Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC 50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC 50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC 50 =3.6-5.8 nM).

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Viral Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > HIV Integrase | Products > Signaling Pathways > HIV

Product Information

• Catalog No.: HY-13238
• CAS No.: 1051375-16-6
• Molecular Formula: C20H19F2N3O5
• Molecular Weight: 419.38
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.62 mg/mL (6.25 mM); Clear solution
• Availability: In-stock

Source

Original product source